Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 117

Sort by

Sort Order Select

Journal Articles

P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

Justin Layer, Sravanti Rangaraju, Santhosh Pasupuleti, Larry D. Cripe, Hamid Sayar, Katie J Sargent, Jill Weisenbach, Huda S. Salman, G. David Roodman, Linsey Mayo, Reuben Kapur, Utpal P Dave', H. Scott Boswell

Blood (2022) 140 (Supplement 1): 11546–11547.

https://doi.org/10.1182/blood-2022-156329

Published: 2022

Journal Articles

Mapping the High-Risk Multiple Myeloma Cell Surface Proteome Identifies T-Cell Inhibitory Receptors for Immune Targeting

Francesco Di Meo, Christina Yu, Annamaria Cesarano, Aljoufi Arafat, Silvia Marino, G David Roodman, Hal E. Broxmeyer, Fabiana Perna

Blood (2021) 138 (Supplement 1): 265.

https://doi.org/10.1182/blood-2021-147483

Published: 2021

Journal Articles

GFI1-Dependent SGPP1 Repression Promotes Growth and Survival of Myeloma Cells

Daniela Nicoleta Petrusca, PhD, Evgeny Berdyshev, PhD, Colin D. Crean, BS, Judith L Anderson, BS, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4387.

https://doi.org/10.1182/blood-2019-131106

Published: 2019

Journal Articles

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Edward Simpson, PhD, Judith L Anderson, BS, Xiang-Qun Xie, PhDMD,MBA, Yunlong Liu, PhD, John Chirgwin, PhD, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4391.

https://doi.org/10.1182/blood-2019-131865

Published: 2019

Journal Articles

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, G. David Roodman, MD PhD, Larry D. Cripe, MD, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Katie J Sargent, RN, Hamid Sayar, MD MSc, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2019) 134 (Supplement_1): 5051.

https://doi.org/10.1182/blood-2019-124384

Published: 2019

Journal Articles

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Jumpei Teramachi, Kazuaki Miyagawa, DDS, PhD, Delgado-Calle Jesus, PhD, Jolene Windle, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4336.

https://doi.org/10.1182/blood-2019-126959

Published: 2019

Journal Articles

Development of a Novel Deep Transfer Learning Framework to Characterize Inter- and Intra-Tumor Heterogeneity in Myeloma Patients

Travis S Johnson, MS, Christina Y Yu, BSc, Chuanpeng Dong, MS, Tongxin Wang, BS, Mohammad Issam Abu Zaid, MBBS, Rafat Abonour, MD, G. David Roodman, MD PhD, Yunlong Liu, PhD, Kun Huang, PhD

Blood (2019) 134 (Supplement_1): 3075.

https://doi.org/10.1182/blood-2019-130452

Published: 2019

Journal Articles

A Highly Robust Model for Predicting Outcome of Multiple Myeloma Patients By Inferring Patient-Specific Transcription Factor Activity

Chuanpeng Dong, MS, Christina Y Yu, BSc, Travis S Johnson, MS, Jill L Reiter, PhD, Mohammad Issam Abu Zaid, MBBS, Rafat Abonour, MD, G. David Roodman, MD PhD, Kun Huang, PhD, Yunlong Liu, PhD

Blood (2019) 134 (Supplement_1): 1785.

https://doi.org/10.1182/blood-2019-131962

Published: 2019

Journal Articles

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Attaya Suvannasankha, MD, Colin Crean, BS, Isaac Carrera Ochoa, G David Roodman, MD PhD, John Chirgwin, PhD

Blood (2018) 132 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2018-99-115680

Published: 2018

Journal Articles

TBK1/Ikkε Inhibitor Amlx Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo

Quanhong Sun, PhD, Peng Zhang, PhDMD, Juraj Adamik, PhD, Konstantinos Lontos, MD, Valentina Marchica, MS, Nicola Giuliani, MD PhD, Rebecca W. Silbermann, MD, G. David Roodman, MD PhD, Deborah Lynn Galson, PhD

Blood (2018) 132 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2018-99-119677

Published: 2018

Journal Articles

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Larry D Cripe, MD, Katie J Sargent, RN, G. David Roodman, MD PhD, Hamid Sayar, MD MSc, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Rajasubramaniam Shanmugam, PhD, Adriana Rogozea, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2018) 132 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2018-99-111181

Published: 2018

Journal Articles

The Gfi1-SphK1 Axis Regulates the Growth and Survival of Myeloma Cells

Daniela Nicoleta Petrusca, PhD, Evgeny Berdyshev, PhD, Patrick Mulcrone, PhD, Colin D. Crean, BS, Judith L Anderson, BS, Quanhong Sun, PhD, Deborah Lynn Galson, PhD, G. David Roodman, MD PhD

Blood (2018) 132 (Supplement 1): 5615.

https://doi.org/10.1182/blood-2018-99-119507

Published: 2018

Journal Articles

A Novel Ex-Vivo Model of Prolonged Osteoblast Suppression in Multiple Myeloma

Noriyoshi Kurihara, DDS, PhD, Yasuhisa Ohata, MD PhD, Gabriel M. Pagnotti, PhD, John Chirgwin, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 4360.

https://doi.org/10.1182/blood.V130.Suppl_1.4360.4360

Published: 2017

Journal Articles

Bone-Targeted Pharmacological Inhibition of Notch Signaling As a Novel Approach to Inhibit Myeloma Growth and Bone Destruction

Jesus Delgado-Calle, PhD, Gerald Wu, Jessica Nelson, Emily G Atkinson, Kevin McAndrews, Lifeng Xiao, Frank H Ebetino, Robert K Boeckman, Jr., David David Roodman, MD PhD, Teresita Bellido

Blood (2017) 130 (Supplement 1): 4419.

https://doi.org/10.1182/blood.V130.Suppl_1.4419.4419

Published: 2017

Journal Articles

Inhibition of p62-ZZ Domain-Mediated Signaling Overcomes Bortezomib Resistance in Multiple Myeloma Cells Independent of Their p53 Status

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Rebecca Silberman, MD, Denise Toscani, PhD, Judith L Anderson, Nicola Giuliani, MD PhD, Xiang-Qun Xie, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 4421.

https://doi.org/10.1182/blood.V130.Suppl_1.4421.4421

Published: 2017

Journal Articles

Aplidin (Plitidepsin) Regulates Viability and Function of Myeloma Cells and Bone Cells in Combination with Other Anti-MM Drugs

Jesus Delgado-Calle, PhD, Emily G Atkinson, Jessica Nelson, Noriyoshi Kurihara, DDS, PhD, Carlos Galmarini, David David Roodman, MD PhD, Teresita Bellido

Blood (2017) 130 (Supplement 1): 3065.

https://doi.org/10.1182/blood.V130.Suppl_1.3065.3065

Published: 2017

Journal Articles

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Attaya Suvannasankha, MD, Rafat Abonour, MD, Sherif Farag, MD PhD, Rebecca W. Silbermann, MD, Sariya Wongsaengsak, MD, Mary Helen Cangany, RN, Anita Rush-Taylor, RN, Mark Tann, MD, Sandra K Althouse, PhD, Susan M Perkins, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1826.

https://doi.org/10.1182/blood.V130.Suppl_1.1826.1826

Published: 2017

Journal Articles

Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells

Gabriel M. Pagnotti, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1775.

https://doi.org/10.1182/blood.V130.Suppl_1.1775.1775

Published: 2017

Journal Articles

Genetic Sost Deletion and Pharmacological Inhibition of Sclerostin Prevent Multiple Myeloma-Induced Bone Loss without Affecting Tumor Growth

Jesus Delgado-Calle, PhD, Judith Anderson, Meloney D. Cregor, Dan Zhou, Lilian I. Plotkin, PhD, Teresita M. Bellido, PhD, G. David Roodman, MD PhD

Blood (2016) 128 (22): 1136.

https://doi.org/10.1182/blood.V128.22.1136.1136

Published: 2016

Journal Articles

EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability

Juraj Adamik, PhD, Rebecca Silbermann, MD, Konstantinos Lontos, MD, Peng Zhang, PhD, Quanhong Sun, Deborah Lynn Galson, PhD, G. David Roodman, MD PhD

Blood (2016) 128 (22): 3247.

https://doi.org/10.1182/blood.V128.22.3247.3247

Published: 2016

NARROW

P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

Mapping the High-Risk Multiple Myeloma Cell Surface Proteome Identifies T-Cell Inhibitory Receptors for Immune Targeting

GFI1-Dependent SGPP1 Repression Promotes Growth and Survival of Myeloma Cells

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Development of a Novel Deep Transfer Learning Framework to Characterize Inter- and Intra-Tumor Heterogeneity in Myeloma Patients

A Highly Robust Model for Predicting Outcome of Multiple Myeloma Patients By Inferring Patient-Specific Transcription Factor Activity

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

TBK1/Ikkε Inhibitor Amlx Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

The Gfi1-SphK1 Axis Regulates the Growth and Survival of Myeloma Cells

A Novel Ex-Vivo Model of Prolonged Osteoblast Suppression in Multiple Myeloma

Bone-Targeted Pharmacological Inhibition of Notch Signaling As a Novel Approach to Inhibit Myeloma Growth and Bone Destruction

Inhibition of p62-ZZ Domain-Mediated Signaling Overcomes Bortezomib Resistance in Multiple Myeloma Cells Independent of Their p53 Status

Aplidin (Plitidepsin) Regulates Viability and Function of Myeloma Cells and Bone Cells in Combination with Other Anti-MM Drugs

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells

Genetic Sost Deletion and Pharmacological Inhibition of Sclerostin Prevent Multiple Myeloma-Induced Bone Loss without Affecting Tumor Growth

EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only